Piramal Pharma posted a net profit of ₹6 crore for the July-September quarter (Q2 FY27), a significant turnaround from a net loss of ₹99 crore in the same period last year. The company’s revenue from operations rose 28% year-on-year (YoY) to ₹2,617 crore, reflecting strong performance across all its businesses. This positive result led to a 15% rally in Piramal Pharma shares.
- Net profit of ₹6 crore in Q2 FY27 versus a ₹99 crore loss last year
- Revenue increased 28% to ₹2,617 crore in Q2 FY27
- EBITDA rose to ₹349 crore with a margin of 13.3%
- Completed 12 regulatory inspections and 110 customer audits in H1FY27
- Upgraded FY27 revenue growth outlook to 19-20%
How did Piramal Pharma improve its financial performance in Q2 FY27?
The company’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) increased to ₹349 crore in Q2 FY27, up from ₹159 crore in the same quarter last year. The EBITDA margin expanded to 13.3%, compared to 7.8% previously. This growth was driven by higher capacity utilisation, operating leverage, disciplined execution, and ongoing cost optimisation efforts.
What operational milestones did Piramal Pharma achieve in H1 FY27?
During the first half of FY27, Piramal Pharma successfully completed 12 regulatory inspections and 110 customer audits. The company maintained a strong compliance record with no official action indicated classifications in US FDA inspections. These achievements demonstrate the company’s commitment to quality and regulatory standards.
Which business segments contributed to Piramal Pharma’s growth?
The Contract Development and Manufacturing Organisation (CDMO) business led growth with a 28% increase, supported by strong order inflows and execution. The Critical Healthcare Group (CHG) business grew 24%, aided by inhalation anesthesia sales outside the US and integration of the Kenalog product. The Consumer Healthcare segment delivered steady 14% growth, driven by strong sales of Power Brands and e-commerce channels.
What is Piramal Pharma’s outlook for the full fiscal year 2027?
Based on strong first-half results and ongoing momentum, Piramal Pharma upgraded its FY27 revenue growth outlook to 19-20%, with expectations of significantly higher profitability. The company anticipates a stronger second half supported by a healthy order book, positive customer engagement, and continued operational discipline.
How has the stock performed recently?
On October 28, 2026, Piramal Pharma’s shares traded at ₹226.81 on the National Stock Exchange, up 14.14% for the day. Since the start of the year, the stock has risen 33%. Over the past month, it gained 10%, and over six months, it surged 38%. The stock reached a 52-week high of ₹231.93 on September 8, 2026, and a 52-week low of ₹132.30 on March 23, 2025. The company’s market capitalisation stood at ₹30,225.60 crore as of October 28, 2026.
In summary, Piramal Pharma’s improved financial results, operational achievements, and positive outlook have contributed to strong investor confidence and share price gains. The company’s focus on execution and quality compliance positions it well for continued growth in FY27.
